S
Saby George
Researcher at Roswell Park Cancer Institute
Publications - 167
Citations - 14398
Saby George is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Nivolumab & Renal cell carcinoma. The author has an hindex of 31, co-authored 138 publications receiving 10182 citations. Previous affiliations of Saby George include Memorial Sloan Kettering Cancer Center & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
Brian I. Rini,Sabina Signoretti,Toni K. Choueiri,David F. McDermott,Robert J. Motzer,Saby George,Thomas Powles,Frede Donskov,Scott S. Tykodi,Sumanta K. Pal,Saurabh Gupta,Chung-Wei Lee,Ruiyun Jiang,Nizar M. Tannir +13 more
TL;DR: In this article , first-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in patients with intermediate/poor-risk sRCC at 42 months minimum follow-up in the CheckMate 214 trial.
Journal ArticleDOI
Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose Interleukin 2 in renal cell carcinoma patients (CTEP#7870).
Roberto Pili,David I. Quinn,Hans J. Hammers,Paul Monk,Saby George,Tanya B. Dorff,Thomas Olencki,Li Shen,Alan D. Hutson,Richard Piekarz,Michael A. Carducci +10 more
TL;DR: A Phase I/II clinical study with entinostat and high dose IL-2 in patients with metastatic clear cell renal cell carcinoma to evaluate the safety, tolerability and efficacy of this combination strategy.
Journal ArticleDOI
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
Jason Zhu,Sarabjot Pabla,Matthew Labriola,Rajan T. Gupta,Shannon J. McCall,Daniel J. George,Devin Dressman,Sean T. Glenn,Mary Nesline,Saby George,Carl Morrison,Tian Zhang +11 more
TL;DR: This data indicates that atezolizumab/bevacIZumab trials in mRCC suggest tumors with high levels of ICI response are likely to be associated with aggressive disease.
Journal ArticleDOI
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
Toni K. Choueiri,Harriet M. Kluger,Saby George,Scott S. Tykodi,Timothy M. Kuzel,Ruth Perets,Suresh Nair,Giuseppe Procopio,Michael A. Carducci,Vincent Castonguay,Edmund Folefac,Chung-Han Lee,Sebastien J. Hotte,Wilson H. Miller,Shruti Shally Saggi,Chung-Wei Lee,Heshani Desilva,Prabhu Bhagavatheeswaran,Robert J. Motzer,Bernard Escudier +19 more
TL;DR: The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program as mentioned in this paper was designed to evaluate multiple immuno-oncology combinations in patients with advanced renal cell carcinoma (aRCC) who progressed during or after prior IO therapy.
Journal ArticleDOI
Is RECIST-defined progression free-survival a meaningful endpoint in the era of immunotherapy?
TL;DR: The phase III CheckMate 025 trial of nivolumab versus everolimus in patients with advanced renal cell carcinoma allowed treatment beyond progression if there was investigator-assessed clinical benefit and tolerability.